176 related articles for article (PubMed ID: 37686184)
1. Potential Association of Cytochrome P450 Copy Number Alteration in Tumour with Chemotherapy Resistance in Lung Adenocarcinoma Patients.
Incze E; Mangó K; Fekete F; Kiss ÁF; Póti Á; Harkó T; Moldvay J; Szüts D; Monostory K
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686184
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
García-Martín E; Pizarro RM; Martínez C; Gutierrez-Martín Y; Pérez G; Jover R; Agúndez JA
Pharmacogenomics; 2006 Jun; 7(4):575-85. PubMed ID: 16753005
[TBL] [Abstract][Full Text] [Related]
3. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
5. Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.
Hofman J; Vagiannis D; Chen S; Guo L
Chem Biol Interact; 2021 May; 340():109448. PubMed ID: 33775687
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.
van Eijk M; Boosman RJ; Schinkel AH; Huitema ADR; Beijnen JH
Cancer Chemother Pharmacol; 2019 Sep; 84(3):487-499. PubMed ID: 31309254
[TBL] [Abstract][Full Text] [Related]
7. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.
Projean D; Morin PE; Tu TM; Ducharme J
Xenobiotica; 2003 Aug; 33(8):841-54. PubMed ID: 12936704
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
9. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.
Nebot N; Crettol S; d'Esposito F; Tattam B; Hibbs DE; Murray M
Br J Pharmacol; 2010 Nov; 161(5):1059-69. PubMed ID: 20977456
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
11. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity.
Kahma H; Aurinsalo L; Neuvonen M; Katajamäki J; Paludetto MN; Viinamäki J; Launiainen T; Filppula AM; Tornio A; Niemi M; Backman JT
Eur J Pharm Sci; 2021 Jul; 162():105810. PubMed ID: 33753217
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
13.
Pu J; Shen J; Zhong Z; Yanling M; Gao J
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):639-647. PubMed ID: 32064933
[TBL] [Abstract][Full Text] [Related]
14. Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line.
Hukkanen J; Lassila A; Päivärinta K; Valanne S; Sarpo S; Hakkola J; Pelkonen O; Raunio H
Am J Respir Cell Mol Biol; 2000 Mar; 22(3):360-6. PubMed ID: 10696073
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.
Diab T; Alkafaas SS; Shalaby TI; Hessien M
Anticancer Agents Med Chem; 2020; 20(13):1582-1591. PubMed ID: 32364081
[TBL] [Abstract][Full Text] [Related]
16. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
[TBL] [Abstract][Full Text] [Related]
17. Comparative molecular profiling of distant metastatic and non-distant metastatic lung adenocarcinoma.
Chen Z; Chen G; Wang Z; Yu J; Zhang H; Mao B; Ma H
Neoplasma; 2021 Mar; 68(2):253-261. PubMed ID: 32940041
[TBL] [Abstract][Full Text] [Related]
18. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.
Dai D; Zeldin DC; Blaisdell JA; Chanas B; Coulter SJ; Ghanayem BI; Goldstein JA
Pharmacogenetics; 2001 Oct; 11(7):597-607. PubMed ID: 11668219
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.
Projean D; Baune B; Farinotti R; Flinois JP; Beaune P; Taburet AM; Ducharme J
Drug Metab Dispos; 2003 Jun; 31(6):748-54. PubMed ID: 12756207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
